Shivani Modi shared a post on X:

“Talk of the town!

KEYNOTE-177 trial shows

mFU: 73.3 months.
Crossover 62 percent
5 year Overall Survival 55 percent vs 44 percent
median Overall Survival 77.5 vs 36.7 months
(2 year Progression-free survival 48.3 percent — CM-8HW72 percent )
Pembrolizumab ? Nivo+İpi?

Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study

Authors: T. André, K.-K. Shiu, T.W. Kim, B.V. Jensen, L.H. Jensen, C.J.A. Punt, D. Smith, R. Garcia-Carbonero, J. Alcaide-Garcia, P. Gibbs, C. de la Fouchardiere, F. Rivera, E. Elez, D.T. Le, T. Yoshino, Y. Zuo, D. Fogelman, D. Adelberg, L.A. Diaz.”

Pembrolizumab vs chemotherapy in MSI-high or MMR-deficient metastatic colorectal cancer

Shivani Modi is a Resident Physician at Jefferson Health, with an interest in pursuing a career in Hematology/Oncology. Previously, she served as a professor at a Mexican medical school and was a research mentor at IMG Helping Hands.